Published in Alzheimer Dis Assoc Disord on August 27, 2010
Globalization of Alzheimer's disease clinical trials. Alzheimers Res Ther (2011) 0.94
The relationship between functional status and judgment/problem solving among individuals with dementia. Int J Geriatr Psychiatry (2012) 0.75
The measurement of observer agreement for categorical data. Biometrics (1977) 216.56
The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology (1993) 47.72
A new clinical scale for the staging of dementia. Br J Psychiatry (1982) 21.77
Sample size and optimal designs for reliability studies. Stat Med (1998) 6.80
Reliability of the Washington University Clinical Dementia Rating. Arch Neurol (1988) 2.48
A goodness-of-fit approach to inference procedures for the kappa statistic: confidence interval construction, significance-testing and sample size estimation. Stat Med (1992) 2.20
Interval estimation for Cohen's kappa as a measure of agreement. Stat Med (2000) 1.65
Reliability of clinical nurse specialists in the staging of dementia. Arch Neurol (1989) 1.41
Sample size requirements for the comparison of two or more coefficients of inter-observer agreement. Stat Med (1998) 1.37
Reliability of monitoring the clinical dementia rating in multicenter clinical trials. Alzheimer Dis Assoc Disord (2004) 1.07
Inference procedures for assessing interobserver agreement among multiple raters. Biometrics (2001) 1.04
Effective number of subjects and number of raters for inter-rater reliability studies. Stat Med (2006) 1.02
Interobserver disagreements on clinical dementia rating assessment: interpretation and implications for training. Alzheimer Dis Assoc Disord (2001) 0.97
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci (2005) 12.85
Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med (2005) 12.04
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Thinning of the cerebral cortex in aging. Cereb Cortex (2004) 8.31
Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science (2010) 8.04
High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA (2008) 7.35
Open Access Series of Imaging Studies (OASIS): cross-sectional MRI data in young, middle aged, nondemented, and demented older adults. J Cogn Neurosci (2007) 7.31
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA (2003) 6.34
Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A (2003) 5.64
TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol (2008) 5.58
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord (2009) 5.50
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex (2008) 5.36
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med (2006) 5.09
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord (2007) 5.01
Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 4.88
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type: evidence from diffusion tensor imaging. Cereb Cortex (2004) 3.87
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol (2003) 3.75
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol (2010) 3.75
Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry (2009) 3.72
Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology (2006) 3.69
Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol (2005) 3.69
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol (2009) 3.60
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Long-term cognitive decline in older subjects was not attributable to noncardiac surgery or major illness. Anesthesiology (2009) 3.56
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol (2013) 3.46
Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol (2009) 3.35
Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology (2007) 3.22
Under-recruitment and nonselective recruitment: dissociable neural mechanisms associated with aging. Neuron (2002) 3.18
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11
Sleep quality and preclinical Alzheimer disease. JAMA Neurol (2013) 3.11
Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. BMJ (2013) 3.05
HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol (2006) 3.00
APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. J Neurosci (2010) 2.99
The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology (2008) 2.91
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ ) deposition. Proc Natl Acad Sci U S A (2010) 2.80
Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging. Neuroimage (2003) 2.77
Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol (2005) 2.76
Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet (2007) 2.73
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol (2008) 2.62
Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A (2008) 2.59
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem (2002) 2.45
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A (2008) 2.44
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol (2009) 2.42
Validity and reliability of the AD8 informant interview in dementia. Neurology (2006) 2.42
Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch Neurol (2008) 2.40
Longitudinal driving performance in early-stage dementia of the Alzheimer type. J Am Geriatr Soc (2003) 2.37
Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology (2002) 2.34
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Perspectives on depression, mild cognitive impairment, and cognitive decline. Arch Gen Psychiatry (2006) 2.29
Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. J Neurosci (2012) 2.26
Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol (2010) 2.25
Large deformation diffeomorphism and momentum based hippocampal shape discrimination in dementia of the Alzheimer type. IEEE Trans Med Imaging (2007) 2.24
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24
Clinical phenotype of Parkinson disease dementia. Neurology (2006) 2.22
Abnormalities of hippocampal surface structure in very mild dementia of the Alzheimer type. Neuroimage (2005) 2.20
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology (2013) 2.19
GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron (2013) 2.13
Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol (2005) 2.11
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
Differential effects of aging and Alzheimer's disease on medial temporal lobe cortical thickness and surface area. Neurobiol Aging (2007) 2.09
Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry (2006) 2.08
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Education and Alzheimer disease without dementia: support for the cognitive reserve hypothesis. Neurology (2007) 2.06
Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry (2006) 2.05
A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet (2005) 2.04
Prediction of on-road driving performance in patients with early Alzheimer's disease. J Am Geriatr Soc (2005) 2.03
Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proc Natl Acad Sci U S A (2004) 1.95
Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res (2010) 1.92
Frontal-hippocampal double dissociation between normal aging and Alzheimer's disease. Cereb Cortex (2004) 1.91
Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects. Alzheimer Dis Assoc Disord (2004) 1.91
Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years. Alzheimers Dement (2008) 1.90
Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics (2006) 1.88
Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system. Arch Neurol (2011) 1.87
Relationship of dementia screening tests with biomarkers of Alzheimer's disease. Brain (2010) 1.80
Mild cognitive impairment is early-stage Alzheimer disease: time to revise diagnostic criteria. Arch Neurol (2006) 1.80
Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol (2003) 1.78
Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab (2003) 1.77
CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood (2010) 1.77
Full genome screen for Alzheimer disease: stage II analysis. Am J Med Genet (2002) 1.77
TGF-β signaling in myeloid cells is required for tumor metastasis. Cancer Discov (2013) 1.76